Intranasal Peptide T in the Treatment of Painful Peripheral Neuropathy of AIDS
This study has been completed.
Sponsor:
Advanced Peptides
Information provided by:
NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:
NCT00002083
First received: November 2, 1999
Last updated: June 23, 2005
Last verified: March 1993
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To compare the effects of intranasal peptide T and placebo in the treatment of painful peripheral neuropathy associated with human immunodeficiency virus (HIV) infection.
| Condition | Intervention |
|---|---|
|
HIV Infections Peripheral Nervous System Disease |
Drug: Peptide T |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Efficacy Study Primary Purpose: Treatment |
| Official Title: | Intranasal Peptide T in the Treatment of Painful Peripheral Neuropathy of AIDS |
Resource links provided by NLM:
Further study details as provided by NIH AIDS Clinical Trials Information Service:
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria
Patients must have:
- Documented HIV-1 infection.
- CD4 count < 500 cells/mm3.
- HIV-1-associated distal symmetrical polyneuropathy, with peripheral neuropathy present for at least 6 weeks prior to study entry.
- Pain severity of at least 8 on an analog scale.
- Prior zidovudine therapy for at least the previous 3 months (unless patient has shown intolerance to zidovudine).
Exclusion Criteria
Co-existing Condition:
Patients with the following symptoms and conditions are excluded:
- Neuropathy due to any other cause besides HIV infection.
- Any symptom consistent with a new or active underlying opportunistic infection or malignancy that could interfere with the evaluation of neuropathy.
- Clinical evidence of new or active CNS disease, potentially from opportunistic infection or neoplasm resulting from HIV infections, that could interfere with the evaluation of neuropathy.
- Other CNS disease (e.g., myelopathy) that could complicate the evaluation of neuropathy.
- Active life-threatening illness other than AIDS.
Concurrent Medication:
Excluded:
- Dapsone.
- Hydralazine.
- Isoniazid (INH).
- Current use of tricyclic antidepressants, anticonvulsants, or clonidine unless the patient has used the drug without a change in dose for at least 3 months prior to study entry.
- Narcotics, unless the patient has been using them for at least 6 weeks prior to study entry.
Prior Medication:
Excluded:
- ddI or ddC in the past 8 weeks.
- Prior peptide T.
- Prior tricyclic antidepressants, anticonvulsants, or clonidine unless they have been used for at least 3 months without change in dose.
- Other investigational drugs within the past 30 days.
Required:
- Zidovudine (if intolerance not demonstrated).
Required:
- Zidovudine for at least the previous 3 months (unless patient has demonstrated intolerance to zidovudine).
Chronic alcohol abuse, or current abuse of psychoactive recreational drugs as defined in DSM IIIR. Patients who may be regarded as unreliable for the study.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00002083
Locations
| United States, Florida | |
| Univ of Miami School of Medicine | |
| Miami, Florida, United States, 33136 | |
| United States, New York | |
| Columbia Presbyterian Med Ctr | |
| New York, New York, United States, 10032 | |
| Saint Luke's - Roosevelt Hosp Ctr | |
| New York, New York, United States, 10019 | |
| Mount Sinai Med Ctr / Klingenstein Clinical Ctr | |
| New York, New York, United States, 10029 | |
Sponsors and Collaborators
Advanced Peptides
More Information
Publications:
MacFadden DK, Doob PR. Role of peptide T in palliation of HIV-1-related painful peripheral neuropathy. Int Conf AIDS. 1991 Jun 16-21;7(2):225 (abstract no WB2173)
| ClinicalTrials.gov Identifier: | NCT00002083 History of Changes |
| Other Study ID Numbers: | 115A, 01 |
| Study First Received: | November 2, 1999 |
| Last Updated: | June 23, 2005 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by NIH AIDS Clinical Trials Information Service:
|
Peptide T HIV-1 Administration, Intranasal Acquired Immunodeficiency Syndrome Peripheral Nervous System Diseases |
Additional relevant MeSH terms:
|
HIV Infections Acquired Immunodeficiency Syndrome Nervous System Diseases Peripheral Nervous System Diseases Lentivirus Infections Retroviridae Infections RNA Virus Infections |
Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Neuromuscular Diseases |
ClinicalTrials.gov processed this record on June 13, 2013